Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002045
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Prospective Double-Blind Study of Retrovir in Early HIV Infection
Sponsor:
Glaxo Wellcome
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Prospective Double-Blind Study of Retrovir in Early HIV Infection
Status:
COMPLETED
Status Verified Date:
1989-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and tolerance of chronic administration of Retrovir AZT to adult patients with early manifestations of HIV disease To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients
120189 Information supplied by drug company update Study discontinued due to positive data from ACTG 016
120189 Information supplied by drug company update Study discontinued due to positive data from ACTG 016
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 15 | None | None | None |